share_log

Ehave Plans Stock Distribution; Mycotopia Therapies Plans To Merge With Ei. Ventures

Ehave Plans Stock Distribution; Mycotopia Therapies Plans To Merge With Ei. Ventures

EHave計劃股票分銷;Mycotopia Treatures計劃與EI合併。風險投資
GlobeNewswire ·  2021/12/08 21:06

Mycotopia and Ei.Ventures announced the signing of an LOI to explore a merger and the formation of PSLY.COM, a $360 Million transaction, and will apply to list shares on NASDAQ; Ehave plans to spin out 30%

Mycotopia和Ei.Ventures宣佈簽署意向書,探索合並和組建PSLY.COM,交易金額為3.6億美元,並將申請在納斯達克上市;Ei.Ventures計劃分拆30%

MIAMI, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the "Company"), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today plans to spin out 30% of its Mycotopia Therapies (OTC: TPIA) shares to existing shareholders on a pro rata basis. Mycotopia Therapies announced Tuesday it had signed an LOI with Ei.Ventures and that the two companies plan to explore a potential merger and formation of PSLY.COM, a $360 Million transaction. Once the transaction is completed, the combined companies will apply to list on NASDAQ.

邁阿密,2021年12月8日(環球通訊社)--eHave,Inc.(場外交易代碼:EHVVF)(以下簡稱“本公司”)是一家為迷幻和精神健康領域提供數字療法的公司,該公司今天宣佈計劃按比例將其Mycotopia Treaties(場外交易代碼:TPIA)的30%股份分拆給現有股東。Mycotopia Treatures週二宣佈,它已與Ei.Ventures簽署了一份意向書,兩家公司計劃探索潛在的合併和組建PSLY.COM的可能性,交易金額為3.6億美元。一旦交易完成,合併後的公司將申請在納斯達克上市。

Ehave controls approximately 9,793,754 shares of Mycotopia Therapies, and the Company plans to spin out a percentage of its shares of the combined companies to its existing shareholders. Ehave acquired its shares in Mycotopia Therapies in December 2020 after its Board of directors elected to sell 100% of its Mycotopia Therapy subsidiary to 20/20 Global for $350,000 and 9,793,754 shares of 20/20 Global stock. 20/20 Global was renamed to Mycotopia Therapies and files audited financial statements with the U. S. Securities and Exchange Commission on EDGAR.

EHave控制着大約9,793,754股Mycotopia Treatures的股份,該公司計劃將合併後公司的一定比例的股份分拆給現有股東。在董事會決定以350,000美元和9,793,754股20/20 Global股票的價格將其Mycotopia Treatment子公司100%出售給20/20 Global後,該公司於2020年12月收購了其在Mycotopia Treaties的股份。20/20 Global更名為Mycotopia Treaties,並向美國證券交易委員會(U.S.Securities and Exchange Commission)提交了關於埃德加的經審計的財務報表。

"Spinning out a portion of Ehave's Mycotopia Therapy shares to our shareholders is an honor and a privilege," said Ben Kaplan, CEO of Ehave. Mr. Kaplan continued, "We knew Mycotopia Therapies would have more potential as its own publicly traded company. Being able to spin out 30% of Ehave's Mycotopia shares to our shareholders is a great way for us to say 'Thank You' for being the best part of our company."

EHave首席執行官本·卡普蘭(Ben Kaplan)表示:“將eHave的部分Mycotopia Treatment股票分拆給我們的股東是一種榮譽和特權。”卡普蘭繼續説:“我們知道,Mycotopia Treatment作為自己的上市公司將更具潛力。能夠將eHave公司Mycotopia公司30%的股份分拆給我們的股東,是我們説‘謝謝’成為我們公司最好的部分的一個很好的方式。”

Mycotopia Therapies is focused on the research, development, and commercialization of novel therapeutics based on naturally-derived psilocybin. Performing most of its research in Jamaica, where psilocybin is legal, Mycotopia Therapies is focused on mushroom and psychedelic opportunities. Mycotopia Therapies is currently working with one of the largest cannabis labs in the Netherlands to develop psychedelics to jointly license certain molecules to be used in psychedelic medicine. Mycotopia Therapies also plans to open psylocibin and ketamine clinics in Jamaica under the direction of a licensed clinical psychiatrist. Mycotopia Therapies' psylocibin and ketamine clinic will be designed to make the most peaceful and serene setting possible to give patients an ideal situation for psychedelic therapies. The primary focus of each clinic will be to help patients heal and reclaim their life under the direction of a licensed clinical psychiatrist.

菌斑療法專注於基於天然裸蓋菇素的新型療法的研究、開發和商業化。在裸蓋菇素合法的牙買加進行了大部分研究,真菌托邦療法專注於蘑菇和迷幻藥物的機會。Mycotopia Treatures目前正在與荷蘭最大的大麻實驗室之一合作開發迷幻劑,以聯合許可某些分子用於迷幻藥物。黴菌治療公司還計劃在牙買加開設木犀草素和氯胺酮診所,由一名有執照的臨牀精神病學家指導。黴菌治療公司的心理菌素和氯胺酮診所將設計成最和平、最寧靜的環境,為患者提供一個理想的迷幻治療環境。每個診所的主要重點將是幫助患者在有執照的臨牀精神病學家的指導下治癒和恢復他們的生活。

Ei.Ventures' flagship botanical psilocybin-based formulation Psilly is a whole-plant botanical psilocybin-based formulation, which is currently in the pre-clinical phase. The goal of the combined companies would be to complete pre-clinical and phase 1 trials and launch therapeutic Psilly into jurisdictions where psilocybin is legal. Psilly is a whole plant and fungi botanical formulation. Ei.Ventures has pioneered using the whole plant and fungi in its botanical formulations, which has the potential to create the "Entourage Effect." Researchers suggest the Entourage Effect could be key to Psilocybin's healing properties. The Entourage Effect is a synergistic interaction between two or more different molecules found within the same plant. Similar to how various strains of cannabis has different effects on the end-user, the same effect is now believed to hold true with Psilocybin mushrooms.

EI.Ventures公司的旗艦植物裸蓋菇素配方Plie是一種全植物裸蓋菇素配方,目前正處於臨牀前階段。合併後的公司的目標將是完成臨牀前和第一階段試驗,並在裸蓋菇素合法的司法管轄區推出治療性Pying。是一種全植物和真菌植物配方。EI.Ventures率先在其植物配方中使用了全植物和真菌,這有可能產生“鼓勵效應”。研究人員認為,環境效應可能是裸蓋菇素治療作用的關鍵。環境效應是在同一植物中發現的兩個或多個不同分子之間的協同作用。就像不同種類的大麻對最終使用者有不同的影響一樣,現在人們認為裸蓋菇素也有同樣的影響。

The distribution plan is subject to Ehave's Board of Directors authorization. A more complete description of the spin-out of Mycotopia Therapies shares to shareholders will be in a forthcoming press release and in our filings with the SEC on the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

分銷計劃須經eHave董事會授權。有關將Mycotopia Treaties股票分拆給股東的更完整描述將在即將發佈的新聞稿中以及我們提交給美國證券交易委員會的美國證券交易委員會網站(www.sec.gov)上的文件中提供。本新聞稿不構成出售或徵求購買任何證券的要約,在任何州或其他司法管轄區,在根據任何此類州或其他司法管轄區的證券法註冊或獲得資格之前,任何州或其他司法管轄區的任何證券出售都不會是非法的。

About Ehave, Inc.

關於eHave,Inc.

Ehave, Inc. is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, psychedelics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes meeting privacy and HIPAA & GDPR Compliant. Our main product is the Ehave Dashboard which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insight using Blockchain technology. The Ehave dashboard offers Offline Encrypted Digital Records Empowering Healthcare providers and patients and it's a powerful machine learning and artificial intelligence platform using artificial intelligence to extract deep insights from audio, video and text to improve research with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools.

EHave,Inc.是一家向患者提供循證治療幹預的數字療法供應商。我們的主要重點是改善治療學的標準護理,通過單獨或與藥物、設備和其他療法一起使用數字療法、迷幻劑和其他療法來預防或治療大腦紊亂或疾病,以優化患者護理和健康結果,滿足隱私和HIPAA&GDPR合規性要求。我們的主要產品是eHave Dashboard,這是一個精神健康信息平臺,允許臨牀醫生使用區塊鏈技術通過數據洞察做出客觀和智能的決策。EHave儀表盤提供離線加密數字記錄,使醫療保健提供者和患者能夠獲得支持,它是一個強大的機器學習和人工智能平臺,使用人工智能從音頻、視頻和文本中提取深刻見解,通過eHave及其領先合作伙伴開發的越來越多的高級工具和應用程序來改進研究。這使得患者、醫療保健提供者和付款人能夠通過使用智能且可訪問的工具,通過高質量、安全和有效的數據驅動參與來解決各種情況。

Forward-Looking Statement Disclaimer

前瞻性聲明免責聲明

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company's research, manufacturing and other development efforts; (ii) the Company's ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company's products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company's industry and introduction of competing products; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.'s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website, .

本新聞稿包含“1995年私人證券訴訟改革法案”所指的“前瞻性陳述”。此類聲明的前綴可能是“打算”、“可能”、“將”、“計劃”、“預期”、“預期”、“計劃”、“預測”、“估計”、“目標”、“相信”、“希望”、“潛在”或類似的詞語。前瞻性陳述基於某些假設,會受到各種已知和未知的風險和不確定性的影響,其中許多風險和不確定性是公司無法控制的,無法預測或量化,因此,實際結果可能與這些前瞻性陳述中明示或暗示的結果大不相同:(I)公司研究、製造和其他開發工作的發起、時間、進展和結果;(Ii)公司推進其產品成功完成開發和商業化的能力;(Iii)製造、開發、商業化的能力。, (4)缺乏足夠的資金為產品開發和業務運營提供資金;(5)公司所在行業內具有競爭力的公司和技術以及競爭產品的推出;(6)公司建立和維持公司合作的能力;(7)關鍵管理人員的流失;(8)公司能夠建立和維持涵蓋其產品的知識產權的保護範圍以及在不侵犯他人知識產權的情況下運營其業務的能力;(Ix)可能未能遵守適用的健康信息隱私和安全法律以及其他州和聯邦隱私和安全法律;以及(X)難以預測美國FDA及其法規的行動。本新聞稿中包含的所有前瞻性陳述僅在本新聞稿發佈之日作出。除非法律要求,否則公司不承擔更新任何書面或口頭前瞻性陳述的義務。有關公司和可能影響前瞻性陳述實現的風險因素的更多詳細信息,請參閲eHave,Inc.於2015年9月24日提交給美國證券交易委員會(美國證券交易委員會)的經修訂的F-1表格註冊聲明中的“風險因素”標題,該聲明可在美國證券交易委員會網站上查閲。

For Investors Relations, please contact:

投資者關係部,請聯繫:

Gabe Rodriguez

加布·羅德里格斯(Gabe Rodriguez)

Phone: (623) 261-9046

電話:(623)261-9046

Email: ir@ehave.com

電子郵件:ir@ehave.com


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論